Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications

References

• Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81:1398–1401.
   PubMed Web of Science ®Google Scholar
• Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia. 2000;14:2–8.
   PubMed Web of Science ®Google Scholar
• Aguayo A, Giles F, Albitar M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma. 2003;44:213–222.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Houck K, Jakeman L, et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13:18–32.
   PubMed Web of Science ®Google Scholar
• Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996;93:1493–1495.
   PubMed Web of Science ®Google Scholar
• Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266:11947–11954.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999;77:527–543.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676.
   PubMed Web of Science ®Google Scholar
• De Bont ES, Rosati S, Jacobs S, et al. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol. 2001;113:296–304.
   PubMed Web of Science ®Google Scholar
• Padrò T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002;16:1302–1310.
   PubMed Web of Science ®Google Scholar
• Bellamy W, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97:1427–1434.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Estey E, Manshouri T, et al. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002;118:151–156.
   PubMed Web of Science ®Google Scholar
• Wimazal F, Krauth MT, Vales A, et al. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma. 2006;47:451–460.
   PubMed Web of Science ®Google Scholar
• Keith T, Araki Y, Ohyagi M, et al. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol. 2007;137:206–215.
   PubMed Web of Science ®Google Scholar
• Savic A, Cemerikic-Martinovic V, Dovat S, et al. Angiogenesis and survival in patients with myelodysplastic syndrome. Pathol Oncol Res. 2012;18:681–690.
   PubMed Web of Science ®Google Scholar
• Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 88–93.
   Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Malcovati L, Rigolin GM, et al. Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes. Leukemia. 2008;22:530–537.
   PubMed Web of Science ®Google Scholar
• Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–967.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Fracchiolla NS, Moronetti Mazzeo L, et al. Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leuk Lymphoma. 2005;46:1345–1351.
   PubMed Web of Science ®Google Scholar
• Gianelli U, Fracchiolla NS, Bucciarelli P, et al. High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes. Am J Clin Pathol. 2013;139:380–387.
   PubMed Web of Science ®Google Scholar
• Cogle CR, Saki N, Khodadi E, et al. Bone marrow niche in the myelodysplastic syndromes. Leuk Res. 2015;39:1020–1027.
   PubMed Web of Science ®Google Scholar
• Rankin EB, Narla A, Park JK, et al. Biology of the bone marrow microenvironment and myelodysplastic syndromes. Mol Genet Metab. 2015;116:24–28.
   PubMed Web of Science ®Google Scholar
• Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505:327–334.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med. 2005;352:536–538.
   PubMed Web of Science ®Google Scholar
• Stasi R, Amadori S, Newland AC, et al. Infliximab chimeric antitumor necrosis factor-α monoclonal antibody as potential treatment for myelodysplastic syndromes. Leuk Lymphoma. 2005;45:509–516.
   Web of Science ®Google Scholar
• Della Porta M. Myelodysplastic syndromes and bone marrow microenvironment. Leuk Res. 2011;35:1442–1443.
   PubMed Web of Science ®Google Scholar
• Lundberg LG, Hellström-Lindberg E, Kanter-Lewensohn L, et al. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. Leuk Res. 2006;30:247–253.
   PubMed Web of Science ®Google Scholar
• Owen MR, Alarcon T, Maini PK, et al. Angiogenesis and vascular remodelling in normal and cancerous tissues. J Math Biol. 2009;58:689–721.
   PubMed Web of Science ®Google Scholar
• Song G, Li Y, Jiang G. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review). Oncol Rep. 2012;28:1935–1944.
   PubMed Web of Science ®Google Scholar
• Legros L, Slama B, Karsenti JM, et al. Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. Ann Hematol. 2012;91:39–46.
   PubMed Web of Science ®Google Scholar
• Gupta P, Mulkey F, Hasserjian RP, et al. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013;31:1311–1320.
   PubMed Web of Science ®Google Scholar
• Wang X, Owzar K, Gupta P, et al. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 2014;78:1005–1013.
   PubMed Web of Science ®Google Scholar
• Yee KWL, Storring JM, Buckstein R, et al. Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Leuk Lymphoma. 2014;55:2669–2671.
   PubMed Web of Science ®Google Scholar
• Mattison R, Jumonville A, Flynn PJ, et al. A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Leuk Lymphoma. 2015;56:2061–2066.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Tibes R, Kadia T, et al. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs. 2015;33:870–880.
   PubMed Web of Science ®Google Scholar